Scroll
A Customer-centric, Innovative
and Reliable CDMO with Global Solutions
One-Stop Services & Solutions
Small Molecules CDMO Services
As a global CDMO (Contract Development and Manufacturing Organization) provider, Porton offers efficient, flexible, and high-quality solutions for custom development and production of small molecule APIs, as well as technical services throughout the entire lifecycle from pre-clinical to commercial to our worldwide partners.
More
Tides CDMO Services
With four major R&D platforms including peptides, oligonucleotides, high-performance liquid chromatography, and Tides analysis, the Porton Tides CDMO Services Platform is committed to providing integrated CMC solutions for global customers, covering all types of new drugs from pre-clinical to commercial.
More
Biologics and Conjugates CDMO Services
One-stop drug development and manufacturing services for biologics and conjugates, including ADCs, AOCs, PDCs, and more.
More
Advanced Therapy Medicinal Products CRO & CDMO Services
We provide end-to-end CRO and CDMO services from cell banking, process development (PD), analytical development (AD), GMP manufacturing, testing to fill & finishing services for plasmid, viral vectors, and mRNA at research, pre-clinical, and commercial st
More
Global Presence
Global Presence
China
-
Chongqing
Headquarters, R&D, GMP
Manufacturing, DS, DP -
Shanghai
Headquarters, R&D, GMP
Manufacturing, DS, DP
Biologics (mAb & ADC)
Jiangxi Yichun Manufacturing Site
GMP Manufacturing, DS
Hubei Xiaogan Manufacturing Site
Manufacturing, RSM
Denmark
Switzerland
Belgium
Starting with small molecule drug manufacturing, Porton has expanded to a versatile range of capabilities supported by strong global professional teams and excellent facilities. Our formulation CDMO and biologics CDMO capabilities are built on the sound foundations of API crystallization, complex formulation, and gene & cell therapy technologies.
Environmental, Social and Corporate Governance
At Porton, we are guided by the ESG principles of “green development, promoting common progress, building a healthy society together, and enhancing corporate governance." These principles drive our sustainable development and our efforts to create greater environmental and social value.
News
Oct 31, 2024
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Oct 24, 2024
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
Oct 14, 2024
Driving innovation and excellence in the CDMO industry, Porton Pharma Solutions 2024 CPHI Europe Review
